Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated June 24, 2026, announces the commencement of a tender offer to acquire Nuvalent, Inc. (NASDAQ: NUVL), a clinical-stage biopharmaceutical company focused on targeted cancer therapies. The transaction is structured through Harmony Row Acquisition Co., a wholly-owned subsidiary of GlaxoSmithKline LLC.
Key Financial Metrics and Transaction Terms
- Offer Price: $124.00 per share in cash, net to the seller, without interest.
- Target Shares: All issued and outstanding Class A and Class B Common Stock of Nuvalent.
- Financing: The offer is not subject to a financing condition.
- Minimum Tender Condition: Validly tendered shares must represent at least a majority of Class A Shares outstanding (including shares already owned by GSK entities).
- Regulatory Conditions: Subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
Note: This filing does not provide GSK's current revenue, profit, cash flow, margins, debt, or liquidity metrics. It references GSK's Q1 2026 Results and FY 2025 Annual Report for such financial data.
Material Changes and Transaction Structure
The filing details a definitive Agreement and Plan of Merger dated June 9, 2026. Upon consummation of the tender offer, the Purchaser will merge with and into Nuvalent under Section 251(h) of the Delaware General Corporation Law. This structure allows the merger to proceed without a vote by Nuvalent's stockholders, provided the tender offer conditions are met. Nuvalent will continue as a direct wholly-owned subsidiary of GSK LLC.
Guidance, Outlook, and Risks
Timeline: The offer expires at 11:59 p.m. Eastern Time on July 14, 2026, unless extended or terminated earlier.
Management Commentary: Nuvalent's Board of Directors has recommended that stockholders accept the offer. GSK utilizes "Core results" (non-IFRS measures) for guidance and does not provide guidance for "Total results" due to unpredictability in fair value movements on contingent consideration.
Risks and Contingencies:
- Failure to meet the Minimum Tender Condition.
- Failure to obtain required regulatory approvals or obtaining them with unfavorable conditions.
- Disruption to Nuvalent's operations, including the retention of key personnel and vendor relationships.
- Transaction costs and potential litigation.
- Forward-looking statements regarding the acquisition's benefits and timing are subject to significant uncertainties.
Investor Verification Checklist
- Verify the full terms of the Offer to Purchase and Letter of Transmittal available at www.readourmaterials.com/gsk2026/.
- Review Nuvalent's Schedule 14D-9 for the Board's recommendation and rationale.
- Confirm the status of the Hart-Scott-Rodino (HSR) antitrust waiting period.
- Check GSK's Q1 2026 Results and FY 2025 Form 20-F for underlying financial health and liquidity to support the cash transaction.
- Monitor for any announcements regarding extensions or amendments to the July 14, 2026, expiration date.